Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-debate-20260410-145418-c1527e7b_20260412-162950",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Critical Evaluation: Mechanistic Hypotheses for AD Clinical Trial Failures\n\n---\n\n## Hypothesis 1: Proteostasis Network Collapse\n\n### Strongest Specific Weakness\n\n**Causality is asserted, not demonstrated.** The hypothesis claims proteostasis collapse is *upstream* of Aβ/tau aggregation and therefore \"predominates.\" However, the cited evidence is entirely correlative. Proteasome activity decreases in AD hippocampus and autophagy-lysosomal dysfunction is present — but Aβ itself can directly impair proteasome function and lysosomal function (refer: Gouras et al., 2000, PMID: 11021936; Ventura et al., 2020, PMID: 31747508). If Aβ accumulation *causes* proteostasis impairment rather than the reverse, the proposed therapeutic strategy (enhancing TFEB/HSF1) targets a downstream consequence and the entire logical architecture collapses.\n\nThe hypothesis also lacks a primary trigger. What causes the initial proteostasis collapse? If the answer is \"Aβ/tau,\" you have circular reasoning. If the answer is aging, then the hypothesis must contend with the fact that proteostasis decline is a universal feature of aging in all neurons, yet not all aged individuals develop AD — which implies a specific initiating event beyond generic proteostasis failure.\n\n### Counter-Evidence and Complications\n\n1. **Familial AD mutations are upstream of proteostasis.** PSEN1/2 and APP mutations cause Aβ overproduction directly, *before* any detectable proteostasis failure. The clear genetic evidence that increased Aβ production is sufficient to initiate disease in familial AD is difficult to reconcile with a model where proteostasis collapse is the upstream, predominating event.\n\n2. **BACE inhibitor trials.** If Aβ production itself is downstream of proteostasis, suppressing Aβ production should be ineffective — consistent with clinical results. But this ignores that FAD mutations prove Aβ production can independently drive disease. The hypothesis must explain how both can be true.\n\n3. **TFEB activation has not demonstrated clinical benefit.** If TFEB is the master therapeutic target and it is upstream, enhancing it should show dramatic benefit. There are no convincing Phase 2/3 data supporting TFEB agonism in AD. This isn't just a timing problem; it suggests either the hypothesis is wrong or TFEB manipulation cannot achieve sufficient proteostasis restoration in human brain — which is itself a major problem for the hypothesis.\n\n4. **Cell-to-cell heterogeneity is ignored.** The cited Keller and Nixon studies use bulk tissue measurements. Proteostasis impairment may be highly localized to specific neuronal populations or subcellular compartments (e.g., synapses vs. soma). The hypothesis implicitly treats neurons as uniform, which is almost certainly incorrect.\n\n### Pointed Question\n\n**If you disrupt Aβ production genetically (e.g., with a BACE inhibitor or γ-secretase modulator) in your TFEB-overexpressing iPSC-AD neurons, does proteostasis marker improvement persist or is it abolished?** If TFEB-enhanced proteostasis *requires* ongoing Aβ accumulation to show its effects, that would falsify the \"upstream\" claim and suggest proteostasis is being regulated by Aβ burden rather than operating independently.\n\n### Confidence Rating: **Moderate**\n\nThe hypothesis is mechanistically appealing and addresses a genuine biological reality — proteostasis does decline in AD. However, the critical upstream positioning is asserted rather than proven, the primary trigger is unspecified, and therapeutic validation through TFEB manipulation has not materialized. The logical structure is vulnerable to the alternative explanation that proteostasis failure is both caused by and contributes to Aβ toxicity in a reinforcing but non-hierarchical cycle. The hypothesis needs a causal mechanism, not just correlative",
  "tokens_used": "956"
}